82 related articles for article (PubMed ID: 3045725)
1. [Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study].
Holtkamp W; Nagel GA
Onkologie; 1988 Jun; 11(3):121-7. PubMed ID: 3045725
[TBL] [Abstract][Full Text] [Related]
2. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
3. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer.
Holtkamp W; Nagel GA; Wander HE; Rauschecker HF; von Heyden D
Int J Cancer; 1984 Sep; 34(3):323-8. PubMed ID: 6480153
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer.
Fritze D; Queisser W; Schmid H; Kaufmann M; Massner B; Westerhausen M; Schmidt R; Edler L; Abel U
Onkologie; 1986 Dec; 9(6):305-12. PubMed ID: 2950359
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
[TBL] [Abstract][Full Text] [Related]
6. Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer.
Peyrat JP; Vennin P; Bonneterre J; Hecquet B; Vandewalle B; Kelly PA; Djiane J
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1363-7. PubMed ID: 6094194
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
[TBL] [Abstract][Full Text] [Related]
8. Perioperative bromocriptine adjuvant treatment for operable breast cancer.
Fentiman IS; Brame K; Chaudary MA; Camplejohn RS; Wang DY; Millis RR
Lancet; 1988 Mar; 1(8586):609-10. PubMed ID: 2894547
[TBL] [Abstract][Full Text] [Related]
9. [Metergoline in hyperprolactinemic breast cancer: a phase II study].
Holtkamp W; Nagel GA
Onkologie; 1986 Oct; 9(5):245-8. PubMed ID: 3101016
[TBL] [Abstract][Full Text] [Related]
10. Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review.
Permana MY; Sarwanti S; Fauziah S
Acta Med Indones; 2023 Oct; 55(4):465-474. PubMed ID: 38213041
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Horti J; Figg WD; Weinberger B; Kohler D; Sartor O
Oncol Rep; 1998; 5(4):893-6. PubMed ID: 9625840
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology of hyperprolactinemia in breast cancer].
Holtkamp W; Wuttke W; Nagel GA; Michel U; Rauschecker H
Onkologie; 1988 Apr; 11(2):86-103. PubMed ID: 3041329
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
Stracke H; Heinlein W; Horowski R; Schatz H
Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
[TBL] [Abstract][Full Text] [Related]
15. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
16. Plasma melatonin in patients with breast cancer.
Falkson G; Falkson HC; Steyn ME; Rapoport BL; Meyer BJ
Oncology; 1990; 47(5):401-5. PubMed ID: 2216295
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine therapy of luteal insufficiency accompanied with hyperprolactinemia in the follicular phase.
Kano T; Nishikawa K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jul; 35(7):975-80. PubMed ID: 6875348
[TBL] [Abstract][Full Text] [Related]
18. Importance of serum prolactin determination in metastatic breast cancer patients.
Mujagić Z; Mujagić H
Croat Med J; 2004 Apr; 45(2):176-80. PubMed ID: 15103755
[TBL] [Abstract][Full Text] [Related]
19. [New results in the field of endocrinology with relevance for medical practice. Hyperprolactemia, endocrine adenomatoses, paraneoplastic hormone secretion and hormone therapy of breast carcinoma].
Geyer G
Wien Med Wochenschr; 1980 Aug; 130(15-16):501-9. PubMed ID: 6258331
[No Abstract] [Full Text] [Related]
20. Estrogen and progesterone receptors in human breast cancer with concomitant assay of plasma 17beta-estradiol, progesterone, and prolactin levels.
Nagai R; Kataoka M; Kobayashi S; Ishihara K; Tobioka N; Nakashima K; Naruse M; Saito K; Sakuma S
Cancer Res; 1979 May; 39(5):1834-40. PubMed ID: 427816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
